abstract |
The present invention relates to the use of microglial cell inhibitors for the manufacture of drugs that inhibit monocyte mediated, macrophage mediated and T cell mediated immune responses, and T cell mediated immune diseases and inflammation not mediated by T cells. It relates to their use for the treatment of reactions. |